[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612470":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":37,"centralContacts":59,"locations":66,"responsibleParty":105,"collaborators":107,"id":115,"slug":116,"hasResults":117,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":117,"sex":122,"minAge":123,"maxAge":124,"enrollmentInfo":125,"targetDuration":36,"studyType":128,"phases":129,"briefSummary":131,"conditions":132,"keywords":136,"overallStatus":69,"whyStopped":36,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":150},{"fullName":5,"class":6},"Monash Medical Centre","OTHER",[8,14,18,21,24,27],{"label":9,"type":10,"description":11,"interventionNames":12},"Anakinra dose 1 IV","ACTIVE_COMPARATOR","Anakinra IV for 21 days",[13],"Drug: Anakinra (Kineret®)",{"label":15,"type":10,"description":16,"interventionNames":17},"Anakinra dose 1 IV\u002FSC","Anakinra IV for 14 days \\& SC for 7 days",[13],{"label":19,"type":10,"description":11,"interventionNames":20},"Anakinra dose 2 IV",[13],{"label":22,"type":10,"description":16,"interventionNames":23},"Anakinra dose 2 IV\u002FSC",[13],{"label":25,"type":10,"description":11,"interventionNames":26},"Anakinra dose 3 IV",[13],{"label":28,"type":10,"description":16,"interventionNames":29},"Anakinra dose 3 IV\u002FSC",[13],[31],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DRUG","Anakinra (Kineret®)","Standard care plus Anakinra for 21 days",[9,15,19,22,25,28],null,[38,42,45,48,50,53,56],{"name":39,"affiliation":40,"role":41},"Marcel F Nold, Prof","Monash Health\u002F Monash University\u002F Hudson Institute of Medical Research","PRINCIPAL_INVESTIGATOR",{"name":43,"affiliation":44,"role":41},"Claudia Nold, Prof","Hudson Institute of Medical Research",{"name":46,"affiliation":47,"role":41},"Rod Hunt, Prof","Monash Health \u002F Monash University",{"name":49,"affiliation":44,"role":41},"Robert Galinsky, Dr",{"name":51,"affiliation":52,"role":41},"Gergely Toldi, Dr","Starship Children's Hospital \u002F Liggins Institute",{"name":54,"affiliation":55,"role":41},"Carl Kirkpatrick, Prof","Monash University",{"name":57,"affiliation":58,"role":41},"David Metz, Dr","Monash Health \u002F Royal Children's Hospital",[60,64],{"name":39,"role":61,"phone":62,"phoneExt":36,"email":63},"CONTACT","+61385723936","marcel.nold@monash.edu",{"name":43,"role":61,"phone":62,"phoneExt":36,"email":65},"claudia.nold@hudson.org.au",[67,87],{"facility":68,"status":69,"city":70,"state":71,"zip":72,"country":73,"countryCode":74,"cosmosGeoPoint":75,"geoPoint":80,"contacts":81},"Monash Children's Hospital","RECRUITING","Clayton","Victoria","3168","Australia","AU",{"type":76,"coordinates":77},"Point",[78,79],145.11667,-37.91667,{"lat":79,"lon":78},[82,86],{"name":83,"role":61,"phone":84,"phoneExt":36,"email":85},"Rebecka Atkinson, RN","+61385722713","rebecka.atkinson@hudson.org.au",{"name":39,"role":41,"phone":36,"phoneExt":36,"email":36},{"facility":88,"status":89,"city":90,"state":91,"zip":92,"country":93,"countryCode":94,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Starship Children's Hospital","NOT_YET_RECRUITING","Grafton","Auckland","1023","New Zealand","NZ",{"type":76,"coordinates":96},[97,98],174.76566,-36.86029,{"lat":98,"lon":97},[101,104],{"name":51,"role":61,"phone":102,"phoneExt":36,"email":103},"+64 93670000","gergely.toldi@auckland.ac.nz",{"name":51,"role":41,"phone":36,"phoneExt":36,"email":36},{"type":106,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR",[108,109,111,113],{"name":55,"class":6},{"name":44,"class":110},"UNKNOWN",{"name":112,"class":6},"Liggins Institute",{"name":114,"class":110},"Starship Children's Hospital of New Zealand","100612470","phase-2-anakinra-pilot-2---a-study-to-optimise-dose-and-route-of-administration-of-anakinra-in-preterm-infants-100612470",false,"NCT07254000","Anakinra Pilot 2 - A Study to Optimise Dose and Route of Administration of Anakinra in Preterm Infants","AP2","Inclusion Criteria:\n\n* Born between 24+0 and 28+6 weeks of gestation\n\nExclusion Criteria:\n\n* Inability of the legal representatives to consent,\n* Genetic syndromes,\n* Severe cardiac anomalies,\n* Substantial pre-\u002Fperinatal compromise,\n* Congenital diaphragmatic hernia,\n* Intrauterine stroke,\n* Conditions that could confound trial results\n* Imminent death or plan for comfort \u002F palliative care\n* Infants born outside the recruiting institutions","ALL","24 Weeks","29 Weeks",{"count":126,"type":127},24,"ESTIMATED","INTERVENTIONAL",[130],"PHASE2","A phase 2 randomised, three-arm, parallel-group, dose-ranging trial to determine safety, efficacy and optimal dosing of intravenous anakinra in premature neonates, with subcutaneous pharmacokinetic sub-study.",[133,134,135],"Premature Infants","Very Premature Infants","Inflammation",[137,138,139,140],"anakinra","bronchopulmonary dysplasia","diffuse white matter injury","very premature infants","2025-11-19",{"date":143,"type":144},"2025-11-28","ACTUAL",{"date":146,"type":144},"2025-06-27",{"date":148,"type":127},"2026-12",{"name":5,"class":6},2]